

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

November 14, 2014

Ascension Orthopedics % Mr. Frederic Testa Regulatory Affairs Director Integra LifeSciences Corporation 311 Enterprise Drive Plainsboro, New Jersey 08536

Re: K142413

Trade/Device Name: INTEGRA® TITAN™ Modular Total Shoulder System

Regulation Number: 21 CFR 888.3660

Regulation Name: Shoulder joint metal/polymer semi-constrained cemented prosthesis

Regulatory Class: Class II Product Code: KWS, HSD Dated: September 15, 2014 Received: September 16, 2014

Dear Mr. Testa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<u>http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</u> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Lori A. Wiggins -S

for
Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K142413 Page 1 of 1

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known)		
K142413		
Device Name INTEGRA® TITAN™ Modular Total Shoulder System		
Indications for Use (Describe)		
The INTEGRA TITAN TM Modular Total Shoulder System is indicated for: Severely painful and/or disabled joint resulting arthritis. Fracture-dislocations of the proximal humerus when from its blood supply or where the surgeon's experience indicated Other difficult clinical problems where shoulder arthrodesis a failed primary component) Shoulder Hemiarthroplasty is all necrosis of the humeral head, Rotator cuff arthropathy, Defointended for cemented or uncemented use. The glenoid comp	from osteoarthritis, traumatic are the articular surface is severely cated that alternative methods of or resection arthroplasty are not a so indicated for: Ununited hume mity and/or limited motion. The	thritis or rheumatoid comminuted, separated treatment are unsatisfactory. acceptable (e.g. – revision of ral head factures, Avascular humeral component is
		e .
Type of Use (Select one or both, as applicable)		
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21	CFR 801 Subpart C)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

807.92(a)(1) – Submitter Information		
Name	Ascension Orthopedics, Inc.	
Address	8700 Cameron Road, Suite 100	
	Austin, TX 78754	
Name of Contact Person	Frederic Testa	
Phone Number	(609) 936-3630	
Fax Number	(609) 275-9445	
Establishment	1651501	
Registration Number		
Date Prepared	November 11 th , 2014	
807.92(a)(2) – Name of device		
Trade or Propriety Name	INTEGRA® TITAN™ Modular Total Shoulder System	
Common or Usual Name	Shoulder Joint Metal/Polymer Semi-Constrained Cemented	
	Prosthesis	
Classification Name	Prostheses, Shoulder, Semi-Constrained, Metal/Polymer	
	Cemented	
Classification Panel	Orthopedic	
Regulation	Class II (under 21CFR 888.3660)	
Product Code	KWS, HSD	

807.92(a)(3) - Legally marketed device(s) to which equivalence is claimed

• Ascension® TITANTM Modular Total Shoulder System (K112438)

807.92(a)(4) - Device description

The TITANTM Modular Total Shoulder System consists of a line of metaphyseal bodies, humeral stems, humeral heads and all polyethylene glenoid components. The body, stem and humeral head may be used by themselves, as a hemiarthroplasty, if the natural glenoid provides a sufficient bearing surface, or in conjunction with the glenoid, as a total replacement. The metaphyseal bodies and humeral stems are shaped to provide proximal fixation and optimal fixation area. Their variable length and proximally-filling shape are designed to accommodate the natural humeral geometry and provide stable fixation, proximal bone loading and proper head placement. The humeral heads are offered with both concentric and eccentric articulating surfaces. The humeral head may articulate against the natural glenoid bone, if it is of sufficient quality, or against the all polyethylene cemented glenoid. The glenoid has multiple options: keeled or standard pegged (3 pegs). All glenoid options are designed to function with both the concentric and eccentric heads.

The humeral components are intended for cemented or uncemented use, while the glenoid component is for use with cement only.

807.92(a)(5) – Intended Use of the device		
Indications for Use	The INTEGRA® TITAN™ Modular Total Shoulder System is	
	indicated for use as a hemi or total shoulder replacement for:	

- Severely painful and/or disabled joint resulting from osteoarthritis, traumatic arthritis or rheumatoid arthritis.
- Fracture-dislocations of the proximal humerus where the articular surface is severely comminuted, separated from its blood supply or where the surgeon's experience indicated that alternative methods of treatment are unsatisfactory.
- Other difficult clinical problems where shoulder arthrodesis or resection arthroplasty are not acceptable (e.g. – revision of a failed primary component)

Shoulder Hemiarthroplasty is also indicated for:

- Ununited humeral head factures
- Avascular necrosis of the humeral head
- Rotator cuff arthropathy
- Deformity and/or limited motion.

The humeral component is intended for cemented or uncemented use. The glenoid component is intended for cemented use only.

807.92(a)(6) Summary of the technological characteristics of the device compared to the predicate

The INTEGRA® TITANTM Modular Total Shoulder System is similar in design and materials to the predicate device, Ascension® TITANTM Modular Total Shoulder System (K112438). The INTEGRA® TITANTM Modular Total Shoulder System has similar indications for use, intended use and fundamental scientific technology as its predicate. The differences between the predicated and proposed device do not raise any new issues regarding safety and effectiveness; therefore, the INTEGRA® TITANTM Modular Total Shoulder System is considered substantially equivalent to the predicate device.

807.92(b)(1-2) – Nonclinical Tests Submitted

Testing to verify the performance of the INTEGRA® TITANTM Modular Total Shoulder System included the following:

- Taper Axial Disassembly Test
- Fatigue Test
- Maximum Static Load Test
- Impact Assembly Test
- Suture Verification Report

The results of these performance tests met their respective acceptance criteria and demonstrate that the INTEGRA® TITANTM Modular Total Shoulder System is safe for the intended use, and is substantially equivalent to the predicate device identified.

807.92(b)(3) – Conclusions drawn from non-clinical data

The design features, materials, intended use, and overall fundamental scientific technology of the INTEGRA® TITANTM Modular Total Shoulder System are substantially equivalent to the predicate device. The safety and effectiveness of the INTEGRA® TITANTM Modular Total Shoulder System is adequately supported by the substantial equivalence information, materials information, and performance data provided within this Premarket Notification submission.